^
    Back
    Association details:
    Biomarker:TDO2 overexpression
    Cancer:Bladder Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Cancer Rep (Hoboken)
    Title:

    TDO2 overexpression correlates with poor prognosis, cancer stemness, and resistance to cetuximab in bladder cancer

    Published date:
    06/07/2021
    Excerpt:
    High TDO2 expression correlated with poor outcome of BC patients...TDO2 promoted BC cells resistance to cetuximab through integration of the EGFR pathway.
    DOI:
    10.1002/cnr2.1417